The Department for Health and Social Care has asked NICE to conduct an appraisal of Lasmiditan within its marketing authorisation for treating acute migraine.
Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-May 2022. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.